EGTX Stock Overview
A pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Egetis Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 5.72 |
| 52 Week High | SEK 9.30 |
| 52 Week Low | SEK 3.83 |
| Beta | 1.44 |
| 11 Month Change | -9.64% |
| 3 Month Change | -30.50% |
| 1 Year Change | 36.52% |
| 33 Year Change | 8.33% |
| 5 Year Change | -66.27% |
| Change since IPO | -66.35% |
Recent News & Updates
Recent updates
Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?
Aug 20
Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation
May 26We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate
Dec 21Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?
Jun 07Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?
Jan 19Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future
Mar 22What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Feb 15Shareholder Returns
| EGTX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 10.4% | 0.7% | 1.1% |
| 1Y | 36.5% | 24.7% | 21.0% |
Return vs Industry: EGTX exceeded the Swedish Biotechs industry which returned 22.7% over the past year.
Return vs Market: EGTX exceeded the Swedish Market which returned 21.8% over the past year.
Price Volatility
| EGTX volatility | |
|---|---|
| EGTX Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: EGTX's share price has been volatile over the past 3 months.
Volatility Over Time: EGTX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 34 | Nicklas Westerholm | www.egetis.com |
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
Egetis Therapeutics AB (publ) Fundamentals Summary
| EGTX fundamental statistics | |
|---|---|
| Market cap | SEK 1.67b |
| Earnings (TTM) | -SEK 319.40m |
| Revenue (TTM) | SEK 70.80m |
23.6x
P/S Ratio-5.2x
P/E RatioIs EGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EGTX income statement (TTM) | |
|---|---|
| Revenue | SEK 70.80m |
| Cost of Revenue | SEK 206.50m |
| Gross Profit | -SEK 135.70m |
| Other Expenses | SEK 183.70m |
| Earnings | -SEK 319.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -1.09 |
| Gross Margin | -191.67% |
| Net Profit Margin | -451.13% |
| Debt/Equity Ratio | 27.1% |
How did EGTX perform over the long term?
See historical performance and comparison